Global Recombinant Human Follicle-stimulating Hormone 麻豆原创 Research Report 2024

Publication ID:

PB504242452

Publication Date:

April 22, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Recombinant Human Follicle-Stimulating Hormone (r-hFSH) is a biotechnologically produced hormone that plays a crucial role in the human reproductive system. It is a synthetic form of the naturally occurring follicle-stimulating hormone (FSH), which is produced by the anterior pituitary gland in the brain. FSH is essential for the regulation of the female and male reproductive systems and is involved in processes like ovarian follicle development, sperm production, and the maturation of reproductive cells.
The global Recombinant Human Follicle-stimulating Hormone market was valued at US$ 1045.6 million in 2023 and is anticipated to reach US$ 1523 million by 2030, witnessing a CAGR of 5.6% during the forecast period 2024-2030.
Increasing Demand for Assisted Reproductive Technologies (ART): The growing acceptance of ART, including in vitro fertilization (IVF), is driving the demand for r-hFSH. ART is used by individuals and couples to address infertility issues, and r-hFSH plays a vital role in controlled ovarian stimulation.
Advancements in ART Procedures: Ongoing advancements in ART procedures are leading to increased use of r-hFSH. These procedures continue to improve success rates, which further fuels demand.
Expanded Indications: The use of r-hFSH is being explored for a broader range of indications, including for individuals with specific hormonal imbalances or other medical conditions that affect reproductive health.
Personalized Medicine: Tailoring treatment regimens to individual patients is gaining importance. Clinicians are increasingly using r-hFSH in personalized fertility treatment plans, optimizing the chances of success while minimizing side effects.
Global Expansion: The use of r-hFSH is expanding globally as countries invest in reproductive healthcare infrastructure. Emerging markets are showing increased demand for fertility treatments and related products.
This report aims to provide a comprehensive presentation of the global market for Recombinant Human Follicle-stimulating Hormone, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Human Follicle-stimulating Hormone.
Report Scope
The Recombinant Human Follicle-stimulating Hormone market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recombinant Human Follicle-stimulating Hormone market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Human Follicle-stimulating Hormone companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Merck
Ferring
Livzon
Gedeon Richter
GenSci
Teva
ChangChun High & New Technology
ABL
Scripps Laboratories
Alphamab Oncology
Hunan Jingfeng Pharmaceutical
Qilu Pharmaceutical
Beijing SL Pharmaceutical
Segment by Type
75IU
150IU
Others
Segment by Application
Infertility Treatment
Assisted Reproductive Technology
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Recombinant Human Follicle-stimulating Hormone companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 75IU
1.2.3 150IU
1.2.4 Others
1.3 麻豆原创 by Application
1.3.1 Global Recombinant Human Follicle-stimulating Hormone 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Infertility Treatment
1.3.3 Assisted Reproductive Technology
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Recombinant Human Follicle-stimulating Hormone 麻豆原创 Perspective (2019-2030)
2.2 Recombinant Human Follicle-stimulating Hormone Growth Trends by Region
2.2.1 Global Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Recombinant Human Follicle-stimulating Hormone Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Recombinant Human Follicle-stimulating Hormone Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Recombinant Human Follicle-stimulating Hormone 麻豆原创 Dynamics
2.3.1 Recombinant Human Follicle-stimulating Hormone Industry Trends
2.3.2 Recombinant Human Follicle-stimulating Hormone 麻豆原创 Drivers
2.3.3 Recombinant Human Follicle-stimulating Hormone 麻豆原创 Challenges
2.3.4 Recombinant Human Follicle-stimulating Hormone 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Recombinant Human Follicle-stimulating Hormone Players by Revenue
3.1.1 Global Top Recombinant Human Follicle-stimulating Hormone Players by Revenue (2019-2024)
3.1.2 Global Recombinant Human Follicle-stimulating Hormone Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Recombinant Human Follicle-stimulating Hormone 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Recombinant Human Follicle-stimulating Hormone Revenue
3.4 Global Recombinant Human Follicle-stimulating Hormone 麻豆原创 Concentration Ratio
3.4.1 Global Recombinant Human Follicle-stimulating Hormone 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Recombinant Human Follicle-stimulating Hormone Revenue in 2023
3.5 Recombinant Human Follicle-stimulating Hormone Key Players Head office and Area Served
3.6 Key Players Recombinant Human Follicle-stimulating Hormone Product Solution and Service
3.7 Date of Enter into Recombinant Human Follicle-stimulating Hormone 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Recombinant Human Follicle-stimulating Hormone Breakdown Data by Type
4.1 Global Recombinant Human Follicle-stimulating Hormone Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Recombinant Human Follicle-stimulating Hormone Forecasted 麻豆原创 Size by Type (2025-2030)
5 Recombinant Human Follicle-stimulating Hormone Breakdown Data by Application
5.1 Global Recombinant Human Follicle-stimulating Hormone Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Recombinant Human Follicle-stimulating Hormone Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size (2019-2030)
6.2 North America Recombinant Human Follicle-stimulating Hormone 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size by Country (2019-2024)
6.4 North America Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size (2019-2030)
7.2 Europe Recombinant Human Follicle-stimulating Hormone 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size by Country (2019-2024)
7.4 Europe Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Recombinant Human Follicle-stimulating Hormone 麻豆原创 Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size (2019-2030)
9.2 Latin America Recombinant Human Follicle-stimulating Hormone 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Recombinant Human Follicle-stimulating Hormone 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Recombinant Human Follicle-stimulating Hormone 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Detail
11.1.2 Merck Business Overview
11.1.3 Merck Recombinant Human Follicle-stimulating Hormone Introduction
11.1.4 Merck Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
11.1.5 Merck Recent Development
11.2 Ferring
11.2.1 Ferring Company Detail
11.2.2 Ferring Business Overview
11.2.3 Ferring Recombinant Human Follicle-stimulating Hormone Introduction
11.2.4 Ferring Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
11.2.5 Ferring Recent Development
11.3 Livzon
11.3.1 Livzon Company Detail
11.3.2 Livzon Business Overview
11.3.3 Livzon Recombinant Human Follicle-stimulating Hormone Introduction
11.3.4 Livzon Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
11.3.5 Livzon Recent Development
11.4 Gedeon Richter
11.4.1 Gedeon Richter Company Detail
11.4.2 Gedeon Richter Business Overview
11.4.3 Gedeon Richter Recombinant Human Follicle-stimulating Hormone Introduction
11.4.4 Gedeon Richter Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
11.4.5 Gedeon Richter Recent Development
11.5 GenSci
11.5.1 GenSci Company Detail
11.5.2 GenSci Business Overview
11.5.3 GenSci Recombinant Human Follicle-stimulating Hormone Introduction
11.5.4 GenSci Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
11.5.5 GenSci Recent Development
11.6 Teva
11.6.1 Teva Company Detail
11.6.2 Teva Business Overview
11.6.3 Teva Recombinant Human Follicle-stimulating Hormone Introduction
11.6.4 Teva Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
11.6.5 Teva Recent Development
11.7 ChangChun High & New Technology
11.7.1 ChangChun High & New Technology Company Detail
11.7.2 ChangChun High & New Technology Business Overview
11.7.3 ChangChun High & New Technology Recombinant Human Follicle-stimulating Hormone Introduction
11.7.4 ChangChun High & New Technology Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
11.7.5 ChangChun High & New Technology Recent Development
11.8 ABL
11.8.1 ABL Company Detail
11.8.2 ABL Business Overview
11.8.3 ABL Recombinant Human Follicle-stimulating Hormone Introduction
11.8.4 ABL Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
11.8.5 ABL Recent Development
11.9 Scripps Laboratories
11.9.1 Scripps Laboratories Company Detail
11.9.2 Scripps Laboratories Business Overview
11.9.3 Scripps Laboratories Recombinant Human Follicle-stimulating Hormone Introduction
11.9.4 Scripps Laboratories Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
11.9.5 Scripps Laboratories Recent Development
11.10 Alphamab Oncology
11.10.1 Alphamab Oncology Company Detail
11.10.2 Alphamab Oncology Business Overview
11.10.3 Alphamab Oncology Recombinant Human Follicle-stimulating Hormone Introduction
11.10.4 Alphamab Oncology Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
11.10.5 Alphamab Oncology Recent Development
11.11 Hunan Jingfeng Pharmaceutical
11.11.1 Hunan Jingfeng Pharmaceutical Company Detail
11.11.2 Hunan Jingfeng Pharmaceutical Business Overview
11.11.3 Hunan Jingfeng Pharmaceutical Recombinant Human Follicle-stimulating Hormone Introduction
11.11.4 Hunan Jingfeng Pharmaceutical Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
11.11.5 Hunan Jingfeng Pharmaceutical Recent Development
11.12 Qilu Pharmaceutical
11.12.1 Qilu Pharmaceutical Company Detail
11.12.2 Qilu Pharmaceutical Business Overview
11.12.3 Qilu Pharmaceutical Recombinant Human Follicle-stimulating Hormone Introduction
11.12.4 Qilu Pharmaceutical Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
11.12.5 Qilu Pharmaceutical Recent Development
11.13 Beijing SL Pharmaceutical
11.13.1 Beijing SL Pharmaceutical Company Detail
11.13.2 Beijing SL Pharmaceutical Business Overview
11.13.3 Beijing SL Pharmaceutical Recombinant Human Follicle-stimulating Hormone Introduction
11.13.4 Beijing SL Pharmaceutical Revenue in Recombinant Human Follicle-stimulating Hormone Business (2019-2024)
11.13.5 Beijing SL Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Merck
Ferring
Livzon
Gedeon Richter
GenSci
Teva
ChangChun High & New Technology
ABL
Scripps Laboratories
Alphamab Oncology
Hunan Jingfeng Pharmaceutical
Qilu Pharmaceutical
Beijing SL Pharmaceutical

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.